


WHO GUIDELINES FOR
THE PHARMACOLOGICAL
AND RADIOTHERAPEUTIC
MANAGEMENT OF
CANCER PAIN IN ADULTS
AND ADOLESCENTS



WHO GUIDELINES FOR
THE PHARMACOLOGICAL
AND RADIOTHERAPEUTIC
MANAGEMENT OF
CANCER PAIN IN ADULTS
AND ADOLESCENTS



World Health
Organization

WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents

ISBN 978-92-4-155039-0

© **World Health Organization 2018**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout: designisgood.info

Printed in Switzerland

CONTENTS

ACKNOWLEDGEMENTS	6
ABBREVIATIONS AND ACRONYMS	8
EXECUTIVE SUMMARY	9
Introduction	9
Aims of the guidelines	9
Scope of the guidelines	9
Guidelines process and decision-making	10
RECOMMENDATIONS	11
1. INTRODUCTION	14
2. OBJECTIVES AND TARGET AUDIENCE OF THESE GUIDELINES	17
3. SCOPE OF THE GUIDELINES	18
4. METHODS USED IN THE GUIDELINES	19
5. CANCER PAIN MANAGEMENT – GUIDING PRINCIPLES	21
5.1. The goal of optimum management of pain is to reduce pain to levels which allow an acceptable quality of life.	21
5.2. Global assessment of the person should guide treatment, recognizing that individuals experience and express pain differently.	21
5.3. Safety of patients, carers, health-care providers, communities and society must be assured.	22
5.4. A pain management plan includes pharmacological treatments and may include psychosocial and spiritual care.	22
5.5. Analgesics, including opioids, must be accessible: both available and affordable.	22
5.6. Administration of analgesic medicine should be given “by mouth”, “by the clock”, “for the individual” and with “attention to detail”.	23
5.7. Cancer pain management should be integrated as part of cancer care.	24
6. RECOMMENDATIONS FOR THE PHARMACOLOGICAL AND RADIOTHERAPEUTIC MANAGEMENT OF CANCER PAIN IN ADULTS AND ADOLESCENTS	25
6.1. Initiation of pain relief	26
6.2. Maintenance of pain relief	29
6.2.1. Choice of opioid	29
6.2.2. Treatment of breakthrough pain	31
6.2.3. Switching or rotating opioid medicines	32
6.2.4. Choosing between immediate-release morphine and slow-release morphine	33
6.2.5. Route of administration of opioids	35
6.3. Cessation of opioid use	36
6.4. Adjuvant medicines for cancer pain management	37
6.4.1. Steroids	37

6.4.2. Antidepressants	39
6.4.3. Anticonvulsants	40
6.5. Management of bone pain	41
6.5.1. Bisphosphonates	41
6.5.2. Monoclonal antibodies	44
6.5.3. Comparison of bisphosphonates or monoclonal antibodies	45
6.5.4. Single-fraction radiotherapy compared with high-fractionated radiotherapy	46
6.5.5. Radioisotopes for bone pain	48
7. RESEARCH AGENDA	50
Interests declared by persons involved in guideline development	51
Funding sources	51
REFERENCES	52
ANNEX 1: EVALUATION OF PAIN	70
1. Brief pain inventory	71
2. Critical Care Pain Observation Tool	74
3. Pain Assessment in Advanced Dementia	75
4. Integrated Palliative Outcomes Scale	76
References	79
ANNEX 2: SYSTEMATIC REVIEW AND GUIDELINE METHODS	81
1. Evidence retrieval and appraisal: methods	81
Search strategy	81
Assessment of study quality and methods of review synthesis	81
2. Evidence to recommendations: methods	84
Group processes used for consensus and disagreement resolution	84
Assessment of the direction and quality of evidence	84
Methods for assessment of values and preferences, acceptability, feasibility and equity	85
How resources were considered	85
Discussion of recommendation strength and evidence quality	85
References	86
ANNEX 3: SYSTEMATIC REVIEW EVIDENCE PROFILES AND EVIDENCE-TO-DECISION TABLES	89
ANNEX 4: BACKGROUND TO THE DEVELOPMENT OF THE GUIDELINES AND DETAILS OF PERSONNEL	90
PICO Questions answered by systematic review	90
Peer review	91
Review and plan for updating these guidelines	91
Plans for dissemination and impact evaluation	92
Derivative products	92
Implementation, adaptation and evaluation	93
Contributors to this publication	93
Systematic review team	93
Network meta-analysis team	94
GRADE methodologist	94

External observers.....	94
WHO Guideline Steering Group.....	94
Characteristics and declarations of interests of the Guideline Development Group.....	96
Characteristics and declarations of interests of the External Review Group.....	100
How competing interests were managed.....	104
ANNEX 5: OPIOID ANALGESICS AND INTERNATIONAL CONVENTIONS.....	105
United Nations drug conventions and their governance system.....	105
The Single Convention on Narcotic Drugs and opioid analgesics.....	106
Drug misuse versus patient need.....	107
Competent national authorities under the international drug control treaties.....	108
The Convention's requirements for national estimates of medical need for opioids.....	108
The importance of reliable estimates.....	109
Domestic manufacture of strong opioid analgesics.....	109
The import/export system for strong opioids.....	110
Requirements for import/export authorizations or certificates.....	112
The reporting system following exportation, importation and consumption of opioids.....	113
Distribution of strong opioids.....	113
Usual requirements for prescribing and dispensing opioids.....	113
World Health Assembly Resolution 67.19 (2014) on Strengthening of palliative care as a component of comprehensive care throughout the life course.....	114
References.....	115
ANNEX 6: PHARMACOLOGICAL PROFILES AND OPIOID CONVERSION TABLES.....	117
I. Pharmacological profiles.....	117
1. Acetylsalicylic acid.....	117
2. Codeine phosphate.....	118
3. Fentanyl.....	119
4. Hydromorphone.....	122
5. Ibuprofen.....	123
6. Methadone.....	124
7. Morphine.....	126
8. Naloxone.....	128
9. Oxycodone.....	128
10. Paracetamol.....	130
II. Typical starting doses.....	131
III. Opioid conversion tables.....	132
IV. Opioid cessation.....	135
References.....	136
ANNEX 7: NETWORK META-ANALYSIS OF EVIDENCE COMPARING ANALGESICS FOR CANCER PAIN MANAGEMENT INITIATION & MAINTENANCE AND FOR BREAKTHROUGH CANCER PAIN.....	137
ANNEX 8: GLOSSARY.....	138

ACKNOWLEDGEMENTS

These guidelines were prepared by the WHO Department for Management of Noncommunicable Diseases, Disability, Violence and Injury Prevention; the Department of Essential Medicines and Health Products; the Department of Service Delivery and Safety; the Department of Mental Health and Substance Abuse; and the Eastern Mediterranean Regional Office, Department of Noncommunicable Disease Management. These departments were represented on the WHO Steering Group for the Medical Management of Cancer Pain in Adults and Adolescents Guidelines.

Responsible technical officer: Dr Cherian Varghese

WHO Steering Group members: Marie-Charlotte Bouesseau, Nicolas Clark, Andre Ilbawi, Taskeen Khan, Nicola Magrini and Slim Slama.

The WHO Department for Management of Noncommunicable Diseases, Disability, Violence and Injury Prevention would like to thank the members of the Guideline Development Group (GDG) for the commitment, enthusiasm and expertise that they contributed.

GDG members: Gauhar Afshan, Zipporah Ali, Chioma Asuzu, Eduardo Bruera, Jim Cleary¹, Malcolm Dobbin, Kathy Foley, Harmala Gupta, Eric Krakauer², Philip Larkin, Diederik Lohman, Sebastien Moine, Hibah Osman, Lukas Radbruch, MR Rajagopal, Paul Sebastian, Nandi Siegfried, Catherine Stannard, Jane Turner, Verna Vanderpuye, Verna Walker-Edwards.

The Department is grateful for the contributions of the guideline External Review Group for peer reviewing the guidelines.

ERG members: Samy Alsirafy, Roger Chou, Michel Daher, Beena Devi, Julia Downing, Andy Gray, Parmanand Jain, Brian Kelly, Emmanuel Luyirika, Geoff Mitchell, Anil Paleri, Tania Pastrana, Nguyen Thi Phuong Cham, Maggie Watson.

预览已结束，完整报告链接和二

<https://www.yunbaogao.cn/report/index/report?rep>